Good day, ladies and gentlemen, and welcome to the Urologix Incorporated Fiscal 2011 second quarter conference call. My name is Karis and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. As a reminder, this conference is being recorded for replay purposes. Statements made at this presentation may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in any forward-looking statements due to risk and uncertainties. A detailed discussion of risks and uncertainties may be found in Urologix recent Annual Report on the Form 10-K for the year ended June 30, 2010 and other documents filed with the Securities and Exchange Commission. At this time, I will turn the call over to Mr. Stryker Warren Jr., Chief Executive Officer. Please precede, sir. Stryker Warren Jr. Good afternoon. This is Stryker Warren and as Chief Executive Officer of Urologix, I welcome you to this earnings call to discuss the company’s results for the second quarter of Fiscal Year 2011. Joining me are Brian Smrdel, the company’s Chief Financial Officer and Greg Fluet, the Executive Vice President and Chief Operating Officer of Urologix.